The RR/UiO Microarray Facility

Introduction on microarrays

Check this excellent multimedia introduction on microarray technologies from Davidson College in North Carolina

Before you start your experiments!

There are many considerations around a microarray experiment, be it expression, genomic profiling, ChIP-chip or other. Please take the time to discuss the options with us before you start. The experimental design and technology used are critical for reliability of results and your ability to draw conclusions from the studies, and the wrong choices can have serious consequences. Our advise at an is free and has no obligations (up to a certain time limit). Please get in touch with the relevant contact.

The Microarray Core Facility (MACF) at Rikshospitalet-Radiumhospitalet (RR) provides its users at RR and the University of Oslo with a range of services within microarray design, production, complete experiment service and data analysis (see Services menu above). The MACF collaborates with the Bioinformatics Core Facility (CFB) to provide extended microarray data analysis services also.

The facility was initiated in 1998 as a priority area at the Norwegian Radium Hospital, and with generous support from the Norwegian Cancer Society a national collaboration with NTNU was initiated that led to the formation of the Norwegian Microarray Consortium (NMC), including also the University of Bergen. The NMC is now responsible also for running the National Microarray Technology Platform under the FUGE program. The RR node is responsible for production of human and custom microarrays and regional support. The FUGE Platforms have recently been reviewed by international committees, with a very positive conclusion for NMC. Our platform also had the highest number of users according to the evaluation of FUGE.

The Core Facility was formally established as part of the RR organisation in 2006 after international review of proposals, and was given a grant of 750 000 NOK per year for 3 years. This funding is used to employ a service scientist and 50% of a scientific manager.

Please excuse: This site is still under construction!